Defining Progression in Metastatic Kidney Cancer
3 विचारों
• 06/26/23
0
0
एम्बेड
administrator
ग्राहकों
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
और दिखाओ
फेसबुक टिप्पणियाँ
SORT BY-
सबसे ऊपर की टिप्पणी
-
नवीनतम टिप्पणियां